Login
$AZTR
$0.63 +$0.00 (0.48%) After hours

$AZTR 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition
10 Nov 2026 8-K: Other Events

Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models

29 Oct 2026 8-K: Other Events

Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors

26 Oct 2026 8-K: Other Events

ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin.

22 Oct 2026 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year

Azitra, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify:

01 Oct 2026 8-K: Other Events

BRANFORD, Conn. – October 1, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the comp...

28 Sep 2026 8-K: Entry into a Material Definitive Agreement

Azitra, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows:

08 Sep 2026 8-K: Regulation FD Disclosure

BRANFORD, Conn. – September 8, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic...

21 Aug 2026 8-K: Other Events

BRANFORD, Conn. – August 21, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic p...

12 Aug 2026 8-K: Results of Operations and Financial Condition

BRANFORD, Conn. – August 12, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic p...

15 Jul 2026 8-K: Other Events

Azitra, Inc. Announces Breakthrough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity

17 Jun 2026 8-K: Other Events

Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond

16 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Azitra, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify:

04 Jun 2026 8-K: Other Events

BRANFORD, Conn. – June 4, 2026 - Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced its 2026 Annual Meeting, originally sch...

27 May 2026 8-K: Other Events

BRANFORD, Conn. – May 27, 2026 - Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to convene its upcoming...

13 May 2026 8-K: Results of Operations and Financial Condition

BRANFORD, Conn. – May 13, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial re...

23 Mar 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This Securities Purchase Agreement (this “Agreement”) is dated as of March 18, 2026, between Azitra, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successor...

13 Mar 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Other Events

BRANFORD, Conn. - March 13, 2026 /PRNewswire/ - Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice fro...

05 Mar 2026 8-K: Other Events

BRANFORD, Conn., March 5, 2026 /PRNewswire/ — Azitra, Inc. (NYSE American: AZTR) (“Azitra” or the “Company”), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announce...

27 Feb 2026 8-K: Results of Operations and Financial Condition

BRANFORD, Conn. – February 27, 2026 — Azitra, Inc. (“Azitra”) (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for th...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support